Research Paper Volume 16, Issue 2 pp 1021—1048

Potential prognosis and immunotherapy predictor TFAP2A in pan-cancer

class="figure-viewer-img"

Figure 9. Experimental validation of the role of TFAP2A in BRCA and COAD. (A) RT-qPGR and Western blot analysis of the PD-L1 mRNA and protein levels, respectively, were determined in MCF-7 and Caco2 cells with TFAP2A overexpression; (B) TFAP2A protein levels in fresh colon cancer tissue (T) and adjacent normal samples (N) (4 pairs) detected by Western blot; (C) Schematic diagram showed the predicted binding site of TFAP2A on PD-L1 promoter and truncated PD-L1 promoter constructs. Relative luciferase activity in HEK-293FT cells co-transfected with the PD-L1 promoter and TFAP2A OE plasmid. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.